诚达药业 (301201)
ChengDa Pharmaceuticals Co.,Ltd.
K-Line Chart
No K-line data available
Company NameChengda Pharmaceutical Co., Ltd.
Listing Date2022-01-20
Issue Price72.69RMB
Registered Capital15471.382410k RMB
Legal RepresentativeGe Jianli
Registered AddressNo. 36 Huanghe Road, Huimin Street, Jiashan County, Jiaxing City, Zhejiang Province
IndustryMedical Services
Main BusinessProvides key pharmaceutical intermediate CDMO services to multinational pharmaceutical companies and pharmaceutical R&D institutions, and engages in the research, development, production, and sales of L-carnitine series products.
Company ProfileChengda Pharmaceutical Co., Ltd. was founded in 1999. It is located in the scenic Hangjiahu Plain - Jiashan Economic and Technological Development Zone (National Level). The company's current production plant is at No. 36 Huanghe Road, covering an area of 123,743 square meters with a building area of 67,760 square meters. The company is a high-tech enterprise with a provincial-level R&D center.
The company mainly produces active pharmaceutical ingredients (APIs), food additives, feed additives, and pharmaceutical intermediates such as antibiotics, anticancer, and antiviral series. Its products are sold to more than 30 countries and regions. The company's self-developed L-carnitine product has been awarded the title of "National Key New Product" and passed the on-site inspection by the US FDA with zero defects in March 2013.
In recent years, the company has developed more than 10 new products annually and has undertaken National Key New Product Program projects, National Torch Program projects, Ministry of Commerce R&D projects, and provincial-level new product projects, obtaining numerous invention patents and utility model patents.
Stock Details
1. Key Indicators
- Total Shares(W): 15471.38
- Circulating A-Shares(W): 10854.43
- Earnings Per Share(RMB): 0.1107
- Net Assets Per Share(RMB): 13.7643
- Operating Revenue(W RMB): 28509.47
- Total Profit(W RMB): 1797.42
- Net Profit Attributable to Parent(W RMB): 1677.33
- Net Profit Growth Rate(%): -58.47
- Weighted Return on Equity(%): 0.7800
- Operating Cash Flow Per Share(RMB): 0.4300
- Undistributed Profit Per Share(RMB): 1.9304
- Capital Reserve Per Share(RMB): 10.9488
2. Main Business
The main business covers:
- Providing key pharmaceutical intermediates and API CDMO R&D and production services for multinational pharmaceutical companies and pharmaceutical R&D institutions.
- R&D, production, and sales of L-carnitine series products and APIs.
- R&D of stem cell drugs.
3. Company Basic Information
- Company Name: ChengDa Pharmaceuticals Co., Ltd.
- Listing Date: 2022-01-20
- Industry: Pharmaceutical Manufacturing
- Address: No. 36 Huanghe Road, Huimin Street, Jiashan County, Jiaxing City, Zhejiang Province, China.
- Website: www.chengdapharm.com
- Company Profile: The company was established as a joint-stock company in 2009 through the overall transformation of its predecessor. It is primarily engaged in pharmaceutical intermediate and API CDMO services, R&D, production, and sales of L-carnitine series products and APIs, and R&D of stem cell drugs.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Shenzhen Shengtai Investment Management Co., Ltd. - Shenzhen Qianhai Shengtai Investment Enterprise (Limited Partnership) | General Legal Person | 1100.69 | 10.14 |
| 2 | Jiashan Huicheng Equity Investment Partnership (Limited Partnership) | General Legal Person | 332.86 | 3.07 |
| 3 | Jiashan Hecheng Equity Investment Partnership (Limited Partnership) | General Legal Person | 263.20 | 2.42 |
| 4 | Shenzhen Jiuheng Investment Advisory Co., Ltd. | General Legal Person | 170.29 | 1.57 |
| 5 | Everbright Securities Asset Management - Industrial Bank - Everbright Securities Asset Management ChengDa Pharmaceuticals Employee Participation in ChiNext Strategic Placement Collective Asset Management Plan | Asset Management Plan | 145.27 | 1.34 |
5. Concept Sectors
- Immunotherapy
- CXO Concept
- Hepatitis Concept
- Innovative Drugs
- Synthetic Biology
- Margin Trading & Securities Lending
- Low-Profit Stock
- Below IPO Price
- Specialized, Refined, Distinctive, and Innovative Enterprises
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information